A Phase 3 interventional study of Interferon beta-1a and Fingolimod in Multiple Sclerosis, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 73 sites in 25 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.
Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 13th largest by enrollment, is one of 3 that started in 2013, is one of 12 in phase 3, and was the 24th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:
TG Therapeutics, Inc. · Sites in United States, Poland, Slovakia
Ages 10–17
Biogen
Ages 10–17
By country, each count listing its studies:
fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 13 · Phase 4 17
First in 2003; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 240 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 167 across the 34 interventional studies. Of the 28 that completed or were terminated, 23 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 34 have an industry lead sponsor. The 6 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
106 studies in Multiple Sclerosis by Novartis: 9 open now, 24 under way, 6 of them phase 3. Of 78 finished, 45 (58%) have results posted.
Among the 106 studies in Multiple Sclerosis by Novartis, this one is the 21st largest by enrollment of the 64 interventional ones that give a count, is one of 4 that started in 2013, is one of 23 in phase 3, reaches primary completion later than 0 of the 23 other live ones, and was the 36th registered.
Novartis’s Multiple Sclerosis studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing fingolimod in Multiple Sclerosis, from their registry updates:
Among Novartis’s 106 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
The study is divided into a Core Phase, which includes the Double-Blind Treatment Period, and an Extension Phase in which all patients will be treated with fingolimod. The Core Phase is a 24-month, double-blind, randomized, active-controlled, parallel-group multicenter study phase to evaluate the efficacy and safety of fingolimod compared to IFN β-1a in children/adolescent patients aged 10-17 years old with MS. The Extension Phase is a 60-month (5 year) study phase for patients who complete the Core Phase of the study and meet all inclusion/exclusion criteria and for patients who will be recruited in the younger cohort to participate in the Extension Phase. The 'younger cohort' refers to the population of pediatric patients fulfilling any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage \<2). The recruitment of the younger cohort (up to 25 patients) was requested as a post- approval health authority commitment
Key Inclusion Criteria Core Phase:
Key Exclusion Criteria Core Phase:
Key Inclusion Criteria Extension Phase:
Applies to all patients participating in the Core Phase and then entering the Extension Phase. 1. Patients that originally met Core Phase Inclusion criteria and completed the Core phase on or off of study drug.
Applies to patients newly recruited to participate in the Extension Phase.
Key Exclusion Criteria Extension Phase:
Applies to patients who completed the Core Phase, but prematurely discontinued study drug.
Premature discontinuation of the study drug during the Core Phase due to:
Applies to patients newly recruited in the younger cohort to participate in the Extension Phase.
1. All newly recruited patients in the younger cohort that enroll directly into the Extension Phase must fulfill the exclusion criteria for the core phase.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fingolimod was administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight) with the aim to achieve systemic exposure in range of that in adults at the licensed 0.5 mg dose. Participants in this arm during core continued into extension and received open-label treatment
Drug: Fingolimod · Drug: Placebo capsule
An intramuscular (IM) injection of Interferon beta-1a was administered once weekly during core phase. Participants switched to receive open-label fingolimod in extension phase
Drug: Interferon beta-1a · Drug: Placebo i.m. injection
The 'younger cohort' refers to the new pediatric patients to be recruited in the extension phase who fulfill any single one or a combination of the following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal (i.e. pubertal status of Tanner stage \<2)
Drug: Fingolimod
Administration once weekly via i.m. injections.
Administrated orally once daily: 0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less.
Matching placebo capsule required for double-dummy masking to blind formulations.
Matching placebo i.m. injection required for double-dummy masking to blind formulations.
Frequency of Relapses in Patients Treated for up to 24 Months
Frequency of relapses assessed by the annualized relapse rate (ARR). The ARR is defined as the average number of confirmed relapses per year (total number of confirmed relapses divided by the total days in the study multiplied by 365.25).
Time frame: 24 months
New/Newly Enlarged T2 Lesions
Annualized rate of the number of new/newly enlarged T2 lesions up to Month 24
Time frame: 24 months
Time to First Relapse
Time to first relapse was determined.
Time frame: 24 months
Proportion of Patients Relapse-free
Proportion of patients relapse-free was determined
Time frame: 24 months
T1 Gd- Enhancing Lesions
Number of T1 Gd-enhancing lesions per scan up to Month 24
Time frame: 24 months
Pharmacokinetics (Cavg) of Fingolimod-P
Cavg (average drug concentration over the dose interval) will be evaluated.
Time frame: 24 months
Pharmacokinetic/Pharmacodynamic Relationship for Fingolimod-P to Lymphocyte Levels
Population PK/PD modeling approaches were used to relate the individual fingolimod-P concentrations to lymphocyte counts.
Time frame: 24 months
| Milestone | Fingolimod | Interferon Beta-1a |
|---|---|---|
| Started | 107 | 108 |
| Full analysis set | 107 | 107 |
| Completed | 100 | 88 |
| Not completed | 7 | 20 |
| Withdrew: Protocol deviation | 0 | 1 |
| Withdrew: Administrative problems | 0 | 1 |
| Withdrew: Patient/guardian decision | 0 | 2 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Adverse event | 3 | 2 |
| Withdrew: Lack of efficacy | 0 | 7 |
| Withdrew: Withdrawal by subject | 3 | 5 |
Frequency of relapses assessed by the annualized relapse rate (ARR). The ARR is defined as the average number of confirmed relapses per year (total number of confirmed relapses divided by the total days in the study multiplied by 365.25).
| Confirmed relapse per year | Fingolimod | Interferon Beta-1a |
|---|---|---|
| Frequency of Relapses in Patients Treated for up to 24 Months | 0.122 (0.078 to 0.192) | 0.675 (0.515 to 0.885) |
Annualized rate of the number of new/newly enlarged T2 lesions up to Month 24
Results for this outcome have not been posted.
Time to first relapse was determined.
Results for this outcome have not been posted.
Proportion of patients relapse-free was determined
Results for this outcome have not been posted.
Number of T1 Gd-enhancing lesions per scan up to Month 24
Results for this outcome have not been posted.
Cavg (average drug concentration over the dose interval) will be evaluated.
Results for this outcome have not been posted.
Population PK/PD modeling approaches were used to relate the individual fingolimod-P concentrations to lymphocyte counts.
Results for this outcome have not been posted.
Collected over Time Frame Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV) for the primary endpoint. All AEs reported in this record are from date of First Patient First Treatment until Last Patient Last Visit for the primary endpoint, up to approximately 4 years. The trial is ongoing.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fingolimod | 0/107 (0%) | 19/107 (17.8%) | 82/107 (76.6%) |
| Interferon Beta-1a | 0/107 (0%) | 10/107 (9.3%) | 94/107 (87.9%) |
| Event | Fingolimod | Interferon Beta-1a |
|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 1/107 | 3/107 |
| LeukopeniaBlood and lymphatic system disorders | 2/107 | 0/107 |
| SeizureNervous system disorders | 2/107 | 0/107 |
| AgranulocytosisBlood and lymphatic system disorders | 1/107 | 0/107 |
| Atrioventricular block second degreeCardiac disorders | 1/107 | 0/107 |
| Supraventricular tachycardiaCardiac disorders | 0/107 | 1/107 |
| Autoimmune uveitisEye disorders | 1/107 | 0/107 |
| UveitisEye disorders | 0/107 | 1/107 |
| DyspepsiaGastrointestinal disorders | 1/107 | 0/107 |
| Gastrointestinal necrosisGastrointestinal disorders | 1/107 | 0/107 |
| Event | Fingolimod | Interferon Beta-1a |
|---|---|---|
| Influenza like illnessGeneral disorders and administration site conditions | 5/107 | 40/107 |
| HeadacheNervous system disorders | 34/107 | 31/107 |
| Viral upper respiratory tract infectionInfections and infestations | 23/107 | 26/107 |
| PyrexiaGeneral disorders and administration site conditions | 8/107 | 21/107 |
| Upper respiratory tract infectionInfections and infestations | 17/107 | 5/107 |
| LeukopeniaBlood and lymphatic system disorders | 14/107 | 3/107 |
| InfluenzaInfections and infestations | 12/107 | 4/107 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/107 | 12/107 |
| ChillsGeneral disorders and administration site conditions | 1/107 | 11/107 |
| DiarrhoeaGastrointestinal disorders | 8/107 | 10/107 |
| Age, Continuous(Years) | Fingolimod | Interferon Beta-1a | Total |
|---|---|---|---|
| Mean | 15.2 ± 2.0 | 15.4 ± 1.60 | 15.3 ± 1.81 |
| Sex: Female, Male(Participants) | Fingolimod | Interferon Beta-1a | Total |
|---|---|---|---|
| Female | 70 | 64 | 134 |
| Male | 37 | 44 | 81 |
| Race (NIH/OMB)(Participants) | Fingolimod | Interferon Beta-1a | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 2 | 5 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 5 |
| White | 100 | 97 | 197 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 2 | 5 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2013 to primary completion in Jul 2017, 47 months.
Results were first posted in Sep 2018, 1 year 2 months after primary completion. A results delay was requested in May 2018.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's 47 months is above that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fingolimod